Clinical trial
SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded…
NCT00009919 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00009919 |
|---|---|
| Title | SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment |
| Official title | Phase II Study of SU5416 (NSC 696819) for Patients With Progressive Metastatic Renal Cancer Failing Prior Biologic Therapy or 5-Fluorouracil Containing Regimens |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer |
| Intervention type | Drug |
| Interventions | semaxanib |
| Enrollment | 50 |
| Start date | Dec 1, 2000 |
| Primary completion | Jun 1, 2003 |
| First posted | Jan 1, 2004 |
| Last update posted | Jan 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: